The Phase I/II GOBLET trial will assess pelareorep plus Tecentriq in pancreatic, colorectal, and anal cancer patients and explore biomarkers of response.
The company presented on the preliminary activity of RMC-4630 combined with Cotellic and said it is studying the SHP2 inhibitor alongside an AstraZeneca drug.
The agency issued a new draft decision memo, outlining various criteria it intends to apply when determining coverage for current and future blood-based CRC screening tests.
Researchers are continuing to collect data on economic, racial, and other factors that could be addressed to make precision medicine access more equitable.
Patients in the Phase II trial will receive infusions of autologous T cells that have been genetically engineered to remove the intracellular checkpoint CISH.
